• Hajime Asano, Mizuki Watanabe, Akinori Kawaguchi, Masashi Yanae, Yoshinori Funakami, Tetsuyuki Wada, Sumio Matzno, Yuzuru Yamazoe, Shozo Nishida, and Seiji Ichida.
• Dept. of Pharmacy, Kinki University Hospital, Faculty of Medicine.
• Gan To Kagaku Ryoho. 2013 Aug 1;40(8):1031-6.

AbstractHiccups are often observed in patients treated with cisplatin(CDDP)-based chemotherapy. It has been reported that gender and specific dosages of CDDP and antiemetic drugs(e.g., dexamethasone and 5-HT3 receptor antagonist)using standard therapy are major risk factors in the onset of hiccups. Recently, aprepitant has been added to the antiemetic therapy in CDDP-based chemotherapy. However, it is not known how the onset of hiccups takes place in antiemetic therapy including aprepitant according to the guideline. In this study, we used cluster analysis to classify 229 patients treated with CDDP-based chemotherapy, to investigate the effect of antiemetic therapy on the onset of hiccups and chemotherapy-induced nausea and vomiting(CINV). Our analysis indicated that aprepitant was not a major risk factor for the onset of hiccups in the high CDDP dose group(≥70 mg/m(2)). However, an effect of antiemesis was confirmed in the standard therapy with aprepitant. In conclusion, we suggest that aprepitant is effective for CINV, without causing the onset of hiccups in patients treated with high-dose CDDP-based chemotherapy.

27 keywords...

hide…